Clinical Report: Cognitive Function and Fatigue in Stable Multiple Sclerosis
Overview
This study evaluates the relationship between cognitive function, fatigue, and various biomarkers in stable multiple sclerosis (MS) patients. Findings indicate that traditional serum biomarkers may not effectively predict cognitive decline or fatigue, while MRI assessments, particularly volumetric measures, show significant correlations.
Background
Cognitive impairment and fatigue are prevalent in multiple sclerosis, affecting a substantial portion of patients and contributing to their overall disability and quality of life. The Expanded Disability Status Scale (EDSS) is commonly used to assess neurological disability, but its correlation with cognitive and fatigue-related issues is limited. Understanding the biomarkers associated with these symptoms is crucial for improving patient management and care.
Data Highlights
No numerical data or trial data provided in the article.
Key Findings
Cognitive impairment affects 34-65% of MS patients, while fatigue impacts up to 95%.
EDSS scores correlate with cognitive decline, but primarily reflect physical disability.
Volumetric MRI measures, particularly of the thalamus and hippocampus, are linked to cognitive performance.
Serum biomarkers like sNfL and sGFAP show limited predictive value for cognition and fatigue in stable MS patients.
TRACK-MS-R, a new cognitive screening tool, demonstrates high sensitivity compared to traditional assessments.
Clinical Implications
Clinicians should prioritize MRI assessments over serum biomarkers when evaluating cognitive function and fatigue in stable MS patients. Utilizing tools like TRACK-MS-R can enhance the detection of cognitive impairment in clinical settings.
Conclusion
The study underscores the importance of MRI and cognitive assessments in understanding fatigue and cognitive decline in MS, suggesting a need for revised clinical approaches to patient evaluation.
These 10 states make it more practical for physicians to participate in hospital ownership by aligning statutory structure, corporate practice of medicine rules, and population trends.
